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Abstract
Background: Oral anticoagulation compromises conventional lupus anticoagulant (LA) screening
assays. Mixing studies can counteract the oral anticoagulant effect but the dilution reduces
sensitivity and can generate false negative results. A firm diagnosis can be made from mixing studies
when an elevated screen ratio is accompanied by a confirm ratio that generates significant
correction to demonstrate phospholipid dependence, but also returns into the reference range,
indicating complete normalisation of the oral anticoagulant effect. Taipan snake venom time (TSVT)
with Ecarin time (ET) as a confirmatory test comprises an oral anticoagulant insensitive LA
detection system and this study investigates the potential impact on detection rates when coupled
with mixing studies on standard assays.
Methods: Eighty patients known to have LA who were receiving oral anticoagulation were tested
with TSVT/ET and 1:1 mixing studies with normal plasma by dilute Russell's viper venom time
(DRVVT) and dilute activated partial thromboplastin time (DAPTT) to assess detection rates by
single and multiple assays.
Results: Thirty three of the 80 samples from known LA positive patients were positive in all three
assays and 15 were positive in combinations of DRVVT, DAPTT or TSVT/ET. The remainder were
positive in only one assay; 12 by DRVVT, 4 by DAPTT and 16 by TSVT/ET. Although all DRVVT
and DAPTT positive mixing studies generated significant correction of the screen ratio by the
confirm ratio, not all confirm ratios corrected back into the reference range. This was the case for
87.5% of the DRVVT results, 44.7% of the DAPTT results and 13.3% of the TSVT/ET positive
mixing tests.
Conclusion: Addition of TSVT/ET screening for LA in orally anticoagulated patients could increase
diagnostic efficacy either by detecting antibodies diluted in the mixing tests of conventional assays
or those that do not react in DRVVT or DAPTT. Additionally, TSVT/ET can affirm the presence of
a LA where conventional assay mixing tests may not have fully counteracted the oral anticoagulant
effect but confirmatory test correction suggests the presence of a LA.
Background
Lupus anticoagulants (LA) comprise part of the heteroge-
neous spectrum of acquired autoantibodies termed
antiphospholipid antibodies (APA) [1]. The occurrence
Published: 6 September 2007
Thrombosis Journal 2007, 5:12 doi:10.1186/1477-9560-5-12
Received: 17 July 2007
Accepted: 6 September 2007
This article is available from: http://www.thrombosisjournal.com/content/5/1/12
© 2007 Moore; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
Thrombosis Journal 2007, 5:12 http://www.thrombosisjournal.com/content/5/1/12and persistence of APA is associated with a wide range of
clinical signs and symptoms, most commonly arterial and
venous thrombosis, recurrent foetal loss and thrombocy-
topenia [2].
LA are identified in the laboratory by their interference
with one or more phospholipid dependent coagulation
assays [3]. Although both national [4] and international
guidelines [5] have been published in recent years for the
laboratory detection of LA, their identification remains a
problem, in part due to the limitations in sensitivity and
specificity of current methodologies [6,7]. Due to the het-
erogeneous nature of the antibodies, more than one LA
sensitive test should be used, of different assay types, in
order to maximise detection rates when screening for LA
[5,6]. Some LA react better in certain test systems than
others or may only be detected in one type of assay [5].
Oral anticoagulant therapy (OAT) can compromise LA
testing on neat plasma so a commonly adopted approach
is to perform screen and confirm assays on 1:1 mixtures
with normal plasma [4]. This will correct the OAT effect in
many cases [1] but the dilution of the antibodies reduces
sensitivity and can lead to false negative results [8]. As in
neat plasma, an elevated screen accompanied by signifi-
cant confirmatory test correction indicates the presence of
a LA, although caution is indicated where the confirma-
tory test does not additionally return into the reference
range as this may indicate incomplete normalisation of
the oral anticoagulant effect [1]. Taipan snake venom time
(TSVT) screening using the Ecarin time (ET) as a confirm-
atory test is a sensitive assay system for detecting LA in
patients on OAT [9] and the present study assesses
whether combination of TSVT/ET analysis with mixing
studies on dilute Russell's viper venom time (DRVVT) and
dilute activated partial thromboplastin time (DAPTT)
could increase detection rates.
Methods
Blood collection, manipulation and storage
Blood was collected into a one tenth volume of 0.105 M
tri-sodium citrate and double centrifuged to obtain
plasma with a platelet count of less than 10 × 109/L as pre-
viously described [10]. The platelet poor plasma for LA
testing was stored at -70°C for no longer than 2 months
and thawed at 37°C for 5 minutes prior to analysis.
Plasma for coagulation screening was analysed fresh,
immediately after centrifugation.
Coagulation screening tests
Coagulation screen comprising prothrombin time,
reported as international normalised ratio (INR), acti-
vated partial thromboplastin time, thrombin time and
Clauss fibrinogen were performed on a Sysmex CA 1500
(Sysmex UK Ltd, Milton Keynes, UK) using Innovin®
recombinant thromboplastin, Actin FS®, Thromboclotin®
and Thrombin-Reagent® (Dade-Behring, Marburg, Ger-
many). Coagulation screens were performed to assess
ongoing anticoagulant therapy and help exclude heparin
therapy or coagulopathies that could mask, mimic or co-
exist with LA.
Lupus anticoagulant assays
LA screening was undertaken on the Sysmex CA1500 ana-
lyser using three assays. DRVVT was performed with Grad-
ipore LA Screen and LA Confirm reagents (BioMérieux UK
Ltd, Basingstoke, UK). DAPTT was performed using PTT-
LA (Diagnostica Stago, Asniéres, France) in the screen
with a platelet neutralisation procedure employing Bio-
data Platelet Extract Reagent (Alpha Laboratories, Hamp-
shire, UK) in the confirmatory test. TSVT/ET analysis was
performed using Diagen Taipan venom (Diagnostic Rea-
gents, Thame, UK) and E. carinatus venom (Diagnostic
Reagents) using an automated version of the previously
described method [9]. All elevated screens received the
confirmatory test plus a screen and confirmatory test on
1:1 mixing studies with normal plasma [2,3]. Lyophilised
Platelet Poor Plasma, (Technoclone, Dorking, UK) was
used as the normal plasma throughout. It is specifically
manufactured to be sufficiently platelet poor for use in LA
assays by careful handling and repeated centrifugation.
LA assay result interpretation criteria
DRVVT, DAPTT and TSVT screen and confirm results were
converted to ratios by dividing the clotting time of the test
by that of the normal control. Interpretation of the data
for the presence of a LA was made by calculating the per-
centage correction of the screening test ratio by the con-
firmatory test ratio. Test plasmas were defined as being
consistent with the presence of a LA if the screening test
ratio was greater than the upper limit of normal and this
was corrected by ≥ 10% [4,8-10]. In view of the potential
compromising effect of OAT on DRVVT and DAPTT in
neat plasma, only the results from 1:1 mixing studies were
assessed for LA activity [4]. Taipan and Ecarin venoms are
largely unaffected by OAT [9] so both neat plasma and
mixing study results were evaluated provided that other
causes of prolonged clotting times were excluded [4,5].
Reference ranges for screen and confirm assays in neat
plasma and 1:1 mixing studies, calculated as ± 2 standard
deviations of the mean were previously locally derived
[4,8,11] from 40 normal donors [4] with normal clotting
screens and no evidence of haemostatic disease.
Patients
DRVVT and DAPTT mixing test and TSVT/ET results on 80
patients known to have LA [4,5] who were receiving OAT
and were positive in at least one of those assays whilst
anticoagulated were assessed to ascertain frequencies of
positivity in each test, and thus, whether addition ofPage 2 of 5
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could increase detection rates in the diagnostic setting.
The study was a retrospective analysis of data generated
for disease/treatment monitoring and all patients gave
verbal consent.
Results
The INRs on the 80 LA patients receiving OAT were within
the range 1.23 – 4.77. Twenty five had INRs below the
therapeutic range of 2.00 – 4.50 and two were above it.
There was no correlation between degree of INR prolon-
gation and screening test value in any of the LA assays.
A total of 56 of 80 (70%) samples were positive in DRVVT
mixing tests, 47 of 80 (58.8%) in DAPTT mixing tests and
58 of 80 (72.5%) in TSVT/ET on neat plasma. The fre-
quencies of LA positivity with single assays and combina-
tions of assays for the 80 LA positive patients on OAT are
shown in Table 1.
The diagnosis of the presence of a LA in mixing studies is
firmer if the confirmatory test ratio not only corrects by ≥
10% but back into the reference range, as this indicates
complete correction of the OAT effect. The frequencies of
correction back into the mixing test specific confirmatory
test reference range or by ≥ 10% but not into the reference
range are shown in Table 2.
Discussion
Therapeutic anticoagulation inevitably compromises
many coagulation assays that are designed to detect a spe-
cific abnormality based on the assumption that the
patient's coagulation is otherwise normal. Use of heparin
neutralisers and mixing studies are available to counteract
these effects but they are not without their limitations and
accurate detection may not be possible [4,8,12]. Whilst it
is rarely necessary to investigate for LA in heparinised
patients it is relatively often required in those who are
receiving OAT [4]. The most frequently used assays to
detect LA in the UK are DRVVT and a variety of APTT
based assays [13]. Testing on neat plasma in these assays
is compromised by OAT giving rise to false-negative and -
positive results in patients with and without LA [4,14,15]
and mixing studies are commonly used to correct the
acquired multiple factor deficiency of OAT.
Although the relatively small dilution in 1:1 mixing stud-
ies can dilute LA to undetectable levels in a significant
number of cases [8], it remains a useful tool for demon-
strating the antibodies in the presence of co-existing coag-
ulopathies providing that the LA is sufficiently potent to
prolong the screening test and a confirmatory test is used
to demonstrate phospholipid dependence. Fifty six of 80
known LA were detected in the DRVVT mixing tests and
47 of 80 by DAPTT mixing tests, so they clearly have a role
to play in detection by commonly used conventional
assays. As would be expected, some antibodies were only
apparent in one of either DRVVT or DAPTT, more so in
DRVVT. However, incomplete normalisation of the OAT
effect can be encountered in patients on high dose OAT
[1,16] so diagnosis of the presence of a LA is more reliable
when the mixing study confirmatory test corrects back
into the reference range whilst the screen remains ele-
vated. Significantly, a very low percentage of DRVVT pos-
itive LA (12.5%) generated a mixing study confirmatory
test correction into the reference range, in contrast to the
55.3% by DAPTT and 44.8% by TSVT/ET. This is likely
due to the specific analyser/reagent/normal plasma com-
bination [14] with this patient population and would not
necessarily be true for other DRVVT/analyser combina-
tions. Incomplete normalisation of the confirmatory test
can also be attributable to avid antibodies [17,18], but
providing that additional coagulopathies are excluded, an
elevated screen in mixing studies with ≥ 10% correction
by a confirmatory test result above the reference range
suggests the presence of a LA. Some such antibodies
appear to possess a degree of resistance to the swamping
effect of high phospholipid confirmatory reagents. This
may explain why so few of the TSVT/ET mixing studies
with elevated screens did not correct back into the refer-
ence range as the ET is a phospholipid independent rea-
gent. Clear positivity in TSVT/ET screening can affirm a
suggestive diagnosis in conventional mixing studies. Of
note is the 48.3% of TSVT/ET positive LA that were unde-












positive for LA 
(%)
33 (41.3) 6 (7.5) 12 (15.0) 4 (5.0) 16 (20.0) 5 (6.2) 4 (5.0)
LA, lupus anticoagulant; DRVVT, dilute Russell's viper venom time; DAPTT, dilute activated partial thromboplastin time; TSVT, Taipan snake venom 
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ously reported for this assay system [8], further
emphasising the limitations imposed by the dilution
effect.
Venoms from the Coastal Taipan (Oxyuranus scutellatus)
and the Saw-scaled viper (Echis carinatus) contain pro-
thrombin activators capable of activating the des-carboxy
prothrombin produced during OAT as well as native pro-
thrombin. The Taipan activator is phospholipid and cal-
cium ion dependent but the Saw-scaled viper activator is
not. Together they represent an alternative or adjunct to
conventional assay mixing tests in detection of LA patients
on OAT. As the DRVVT and DAPTT positive LA were
detected using mixing studies, it is unsurprising that more
than half were also detectable by TSVT/ET as they would
have been potent antibodies and more likely to present in
multiple assays. Nevertheless, 27.5% were not detected in
TSVT/ET, a clear manifestation of antibody heterogeneity,
and likewise, those LA that were positive in TSVT/ET and
just one of either DRVVT and DAPTT. Of particular rele-
vance to this study are the 20.0% that were detectable only
by TSVT/ET. Irrespective of whether these LA were TSVT/
ET detectable only and/or would have presented in
DRVVT and/or DAPTT without the OAT effect, there are
clear implications for initial diagnostic LA screening on
patients receiving OAT. Extrapolating these findings in
known LA to the diagnostic setting, use of TSVT/ET would
increase detection rates by detecting LA that would be
diluted out in DRVVT and DAPTT mixing tests, and also
those that are undetectable in conventional assays, prob-
ably as a result of antibody heterogeneity and epitope spe-
cificity. This should not however engender a false sense of
security as some LA that are only detectable in DRVVT or
DAPTT will be negative in TSVT and diluted in mixing
studies.
Additionally, spontaneous variation of APA has been
reported to occur in up to 25% of cases [19] and TSVT/ET
analysis could have a role in disease monitoring for
patients on OAT whose antibody presentation or avidity
changes over time [20].
Conclusion
There is sufficient evidence to suggest that conventional
screening for LA on neat plasma in patients receiving OAT
is unreliable. Mixing studies are widely used and can
detect LA in some patients but are not undertaken by all
laboratories [13], resulting in the possibilities of either
inaccurate diagnostic outcomes or non-performance of LA
screening in this patient group. TSVT/ET screening can
detect LA missed in conventional assays due to non-reac-
tivity in those tests or dilution to undetectable levels in
mixing studies. In other patients where the mixing tests
are positive but the confirmatory assay does not correct
back into the reference range, clearly positive TSVT/ET
results affirm diagnosis. Although TSVT/ET mixing studies
are unnecessary for correction of the OAT effect, they
should still be used with this assay system alongside test-
ing on neat plasma to demonstrate inhibition and
enhance specificity. Addition of TSVT/ET screening to an
existing repertoire of conventional assays has the poten-
tial to improve detection rates in a group of patients where
LA identification is difficult.
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